{
  "id": 278919,
  "title": "Liposomal Chemo Combination No Better Than Standard Induction in Pediatric AML",
  "url": "https://urgent.news/2026/08/07/liposomal-chemo-combination-no-better-than-standard-induction-in",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-07T19:55:04.000Z",
  "source": {
    "name": "MedPage Today",
    "slug": "medpage-today",
    "url": "https://www.medpagetoday.com/hematologyoncology/leukemia/122535"
  },
  "original_language": "en",
  "account": "A recent clinical trial conducted by the Children's Oncology Group indicates that a liposomal daunorubicin and cytarabine combination is not superior to the standard induction therapy in pediatric acute myeloid leukemia (AML) patients. The research, led by Todd Cooper, DO, of Seattle Children's Hospital, compared the outcomes of patients treated with either the standard or liposomal treatment. The study found that the 2-year event-free survival rate was lower in the liposomal group for low-risk AML patients (57.5% vs 73.8%, P=0.001), suggesting the combination may not be optimal for this patient group.",
  "summary": "A phase III trial conducted by the Children's Oncology Group has found that liposomal daunorubicin and cytarabine (Vyxeos) is no better than the standard induction therapy of daunorubicin and cytarabine in children and young adults with newly diagnosed acute myeloid leukemia (AML). The study, published in the Journal of Clinical Oncology, showed that while the 2-year event-free survival (EFS) rate was higher with standard induction therapy in patients with FLT3 wild-type AML, it was significantly lower in patients with low-risk disease assigned to liposomal treatment. The trial also revealed that the 2-year cumulative incidence of relapse was higher in the liposomal group. The researchers suggest that alternative therapeutic strategies that mitigate cardiotoxicity while improving survival are essential, as anthracyclines are crucial for cure but are associated with significant acute and late toxicities in pediatric AML survivors.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}